Table of Contents Author Guidelines Submit a Manuscript
International Journal of Chronic Diseases
Volume 2014 (2014), Article ID 127426, 5 pages
http://dx.doi.org/10.1155/2014/127426
Clinical Study

Evaluation of the Mean Platelet Volume and Red Cell Distribution Width in FMF: Are They Related to Subclinical Inflammation or Not?

1Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Sutcu Imam University, 46050 Kahramanmaras, Turkey
2Division of Hematology, Department of Pediatrics, School of Medicine, Sutcu Imam University, 46050 Kahramanmaras, Turkey
3Department of Internal Medicine, School of Medicine, Sutcu Imam University, 46050 Kahramanmaras, Turkey
4Division of Rheumatology, Department of Internal Medicine, School of Medicine, Ondokuz Mayis University, 55000 Samsun, Turkey

Received 28 November 2013; Revised 2 February 2014; Accepted 5 February 2014; Published 12 March 2014

Academic Editor: Tadeusz Robak

Copyright © 2014 Gozde Yildirim Cetin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. P. H. Drenth and J. W. M. van der Meer, “Hereditary periodic fever,” The New England Journal of Medicine, vol. 345, no. 24, pp. 1748–1757, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Onen, “Familial Mediterranean fever,” Rheumatology International, vol. 26, no. 6, pp. 489–496, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Fonnesu, C. Cerquaglia, M. Giovinale et al., “Familial Mediterranean fever: a review for clinical management,” Joint Bone Spine, vol. 76, no. 3, pp. 227–233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Livneh, P. Langevitz, D. Zemer et al., “The changing face of familial Mediterranean fever,” Seminars in Arthritis and Rheumatism, vol. 26, no. 3, pp. 612–627, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. H. J. Lachmann, B. Şengül, T. U. Yavuzşen et al., “Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations,” Rheumatology, vol. 45, no. 6, pp. 746–750, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Ben-Zvi and A. Livneh, “Chronic inflammation in FMF: markers, risk factors, outcomes and therapy,” Nature Reviews Rheumatology, vol. 7, no. 2, pp. 105–112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Korkmaz, H. Ozdogan, O. Kasapçopur, and H. Yazici, “Acute phase response in familial Mediterranean fever,” Annals of the Rheumatic Diseases, vol. 61, no. 1, pp. 79–81, 2002. View at Google Scholar
  8. T. F. Thurmon, “Genetics, aging, and the heart,” The Journal of the Louisiana State Medical Society, vol. 150, no. 8, pp. 356–366, 1998. View at Google Scholar · View at Scopus
  9. A. Frensdorff, E. Sohar, and H. Heller, “Plasma fibrinogen in familial Mediterranean fever,” Annals of Internal Medicine, vol. 55, pp. 448–455, 1961. View at Google Scholar · View at Scopus
  10. A. Yesil, E. Senates, I. V. Bayoglu, E. D. Erdem, R. Demirtunc, and A. O. Kurdas Ovunc, “Red cell distribution width: a novel marker of activity in inflammatory bowel disease,” Gut and Liver, vol. 5, no. 4, pp. 460–467, 2011. View at Google Scholar
  11. Z. Förhécz, T. Gombos, G. Borgulya, Z. Pozsonyi, Z. Prohászka, and L. Jánoskuti, “Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state,” American Heart Journal, vol. 158, no. 4, pp. 659–666, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. P. M. W. Bath and R. J. Butterworth, “Platelet size: measurement, physiology and vascular disease,” Blood Coagulation and Fibrinolysis, vol. 7, no. 2, pp. 157–161, 1996. View at Google Scholar · View at Scopus
  13. A. Y. Gasparyan, L. Ayvazyan, D. P. Mikhailidis, and G. D. Kitas, “Mean platelet volume: a link between thrombosis and inflammation?” Current Pharmaceutical Design, vol. 17, no. 1, pp. 47–58, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Milovanovic, E. Nilsson, and P. Järemo, “Relationships between platelets and inflammatory markers in rheumatoid arthritis,” Clinica Chimica Acta, vol. 343, no. 1-2, pp. 237–240, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. R. D. Baynes, R. D. V. Lamparelli, W. R. Bezwoda, A. J. Gear, N. Chetty, and P. Atkinson, “Platelet parameters—part II: platelet volume-number relationships in various normal and disease states,” South African Medical Journal, vol. 73, no. 1, pp. 39–43, 1988. View at Google Scholar · View at Scopus
  16. B. Kisacik, A. Tufan, U. Kalyoncu et al., “Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis,” Joint Bone Spine, vol. 75, no. 3, pp. 291–294, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. N. Kapsoritakis, M. I. Koukourakis, A. Sfiridaki et al., “Mean platelet volume: a useful marker of inflammatory bowel disease activity,” American Journal of Gastroenterology, vol. 96, no. 3, pp. 776–781, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Yazici, M. Yazici, B. Erer et al., “The platelet functions in patients with ankylosing spondylitis: anti-TNF-α therapy decreases the mean platelet volume and platelet mass,” Platelets, vol. 21, no. 2, pp. 126–131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Lippi, G. Targher, M. Montagnana, G. L. Salvagno, G. Zoppini, and G. C. Guidi, “Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients,” Archives of Pathology & Laboratory Medicine, vol. 133, no. 4, pp. 628–632, 2009. View at Google Scholar
  20. E. Erdem, D. Erdem, M. Dilek et al., “Red cell distribution width and mean platelet volume in amyloidosis,” Clinical and Applied Thrombosis/Hemostasis, 2012. View at Publisher · View at Google Scholar
  21. N. Gang, J. P. H. Drenth, P. Langevitz et al., “Activation of the cytokine network in familial Mediterranean fever,” Journal of Rheumatology, vol. 26, no. 4, pp. 890–897, 1999. View at Google Scholar · View at Scopus
  22. S. Kiraz, I. Ertenli, M. Arici et al., “Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever,” Clinical and Experimental Rheumatology, vol. 16, no. 6, pp. 721–724, 1998. View at Google Scholar · View at Scopus
  23. S. Haznedaroglu, M. A. Öztürk, B. Sancak et al., “Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever,” Clinical and Experimental Rheumatology, vol. 23, no. 4, pp. S77–S80, 2005. View at Google Scholar · View at Scopus
  24. I. Simsek, S. Pay, A. Pekel et al., “Serum proinflammatory cytokines directing T helper 1 polarization in patients with familial Mediterranean fever,” Rheumatology International, vol. 27, no. 9, pp. 807–811, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Erken, H. T. E. Ozer, and R. Gunesacar, “Plasma interleukin-10 and interleukin-12 levels in patients with familial Mediterranean fever,” Rheumatology International, vol. 26, no. 9, pp. 862–864, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. G. P. Manukyan, K. A. Ghazaryan, Z. A. Ktsoyan et al., “Cytokine profile of Armenian patients with familial Mediterranean fever,” Clinical Biochemistry, vol. 41, no. 10-11, pp. 920–922, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Notarnicola, M. N. Didelot, F. Seguret, J. Demaille, and I. Touitou, “Enhanced cytokine mRNA levels in attack-free patients with familial Mediterranean fever,” Genes and Immunity, vol. 3, no. 1, pp. 43–45, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Köklü, M. A. Öztürk, M. Balci, O. Yüksel, I. Ertenli, and S. Kiraz, “Interferon-gamma levels in familial Mediterranean fever,” Joint Bone Spine, vol. 72, no. 1, pp. 38–40, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Clarke, P. W. M. Johnson, R. E. Banks et al., “Effects of interleukin 6 administration on platelets and haemopoietic progenitor cells in peripheral blood,” Cytokine, vol. 8, no. 9, pp. 717–723, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Balci, K. Tinaztepe, E. Yilmaz et al., “MEFV gene mutations in familial Mediterranean fever phenotype II patients with renal amyloidosis in childhood: a retrospective clinicopathological and molecular study,” Nephrology Dialysis Transplantation, vol. 17, no. 11, pp. 1921–1923, 2002. View at Google Scholar
  31. A. Livneh, “Amyloidosis of Familial Mediterranean Fever (FMF)—insights to FMF phenotype II,” Harefuah, vol. 145, no. 10, pp. 743–782, 2006. View at Google Scholar · View at Scopus
  32. M. Tunca, G. Kirkali, M. de Soytürk, S. Akar, M. B. Pepys, and P. N. Hawkins, “Acute phase response and evolution of familial Mediterranean fever,” The Lancet, vol. 353, no. 9162, p. 1415, 1999. View at Google Scholar · View at Scopus
  33. A. Mor, Y. Shinar, N. Zaks et al., “Evaluation of disease severity in familial Mediterranean fever,” Seminars in Arthritis and Rheumatism, vol. 35, no. 1, pp. 57–64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Gershoni-Baruch, R. Brik, M. Lidar, M. Shinawi, and A. Livneh, “Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation,” Journal of Rheumatology, vol. 30, no. 2, pp. 308–312, 2003. View at Google Scholar · View at Scopus
  35. S. Padeh, Y. Shinar, E. Pras et al., “Clinical and diagnostic value of genetic testing in 216 Israeli children with familial Mediterranean fever,” Journal of Rheumatology, vol. 30, no. 1, pp. 185–190, 2003. View at Google Scholar · View at Scopus
  36. C. A. Dinarello, S. M. Wolff, S. E. Goldfinger, D. C. Dale, and D. W. Alling, “Colchicine therapy for familial Mediterranean fever. A double blind trial,” The New England Journal of Medicine, vol. 291, no. 18, pp. 934–937, 1974. View at Google Scholar · View at Scopus
  37. S. E. Goldfinger, “Colchicine for familial Mediterranean fever,” The New England Journal of Medicine, vol. 287, no. 25, p. 1302, 1972. View at Google Scholar · View at Scopus
  38. D. Zemer, M. Revach, M. Pras et al., “A controlled trial of colchicine in preventing attacks of familial Mediterranean fever,” The New England Journal of Medicine, vol. 291, no. 18, pp. 932–934, 1974. View at Google Scholar · View at Scopus
  39. Z. B. Ozçakar, F. Yalçinkaya, S. Yüksel, B. Acar, D. Gökmen, and M. Ekim, “Possible effect of subclinical inflammation on daily life in familial Mediterranean fever,” Clinical Rheumatology, vol. 25, no. 2, pp. 149–152, 2006. View at Google Scholar
  40. A. Duzova, A. Bakkaloglu, N. Besbas et al., “Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever,” Clinical and Experimental Rheumatology, vol. 21, no. 4, pp. 509–514, 2003. View at Google Scholar · View at Scopus
  41. N. Tweezer-Zaks, E. Rabinovich, M. Lidar, and A. Livneh, “Interferon-α as a treatment modality for colchicine-resistant familial Mediterranean fever,” Journal of Rheumatology, vol. 35, no. 7, pp. 1362–1365, 2008. View at Google Scholar · View at Scopus